FDA approves Ziihera in first-line HER2+ advanced gastroesophageal adenocarcinoma
U.S. FDA approves Ziihera® (zanidatamab-hrii) with and without tislelizumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals said Ziihera U.S. prescribing information includes boxed warnings for diarrhea and embryo-fetal toxicity.
JAZZ•
